Recent News

• 12.04.2025 - Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
• 12.03.2025 - Virax Biolabs Group Limited Announces $5 Million Private Placement
• 12.03.2025 - Virax Biolabs’ CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders
• 12.03.2025 - Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders
• 11.03.2025 - Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes
• 08.28.2025 - Virax Biolabs COO, Dr Nigel McCracken, Discusses Immune Decoding with ViraxImmuneTM on the MedTech Gurus Podcast
• 08.26.2025 - Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early SeptemberV
• 08.26.2025 - Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September
• 08.08.2025 - Major New Study Reveals Immunological Insights Into ME/CFS, Further Supporting Blood-based Diagnostic Testing and Research
• 07.30.2025 - ELISA vs ELISpot: Select The Right Assay For Your Research

Recent Filings

• 12.02.2025 - EX-99.1 EX-99.1
• 12.02.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.29.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.29.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.29.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.29.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]